COSCIENS Biopharma Inc. balance sheet CSCIF

Annual Quarterly

As of Dec 31, 2025, COSCIENS Biopharma Inc. had total assets of $21.4 million and total liabilities of $17.6 million. Total assets were down 38.9% from a year earlier. It held $7.3 million in cash and investments against $2.1 million of total debt, net cash of $5.2 million. The current ratio, current assets divided by current liabilities, was 3.18.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
Assets
Cash
7
-55.4%
16
+145.5%
7
-34.5%
10
+65.5%
6
-74.6%
24
+209.7%
8
-46.0%
15
+86.5%
8
Cash and investments
7
-55.4%
16
+145.5%
7
-34.5%
10
+65.5%
6
-74.6%
24
+209.7%
8
-46.0%
15
+86.5%
8
Receivables
1
-46.5%
2
+712.8%
0
-60.4%
1
-44.3%
1
-21.8%
2
+155.5%
1
+123.8%
0
+33.0%
0
Inventory
1
-51.4%
3
-32.9%
4
—
—
—
—
—
—
Total current assets
12
-52.0%
24
+112.8%
11
-79.7%
55
-21.6%
71
+156.5%
28
+153.1%
11
-32.9%
16
+73.3%
9
Property and equipment, net
10
-10.6%
11
-5.8%
12
+5291.2%
0
+12.5%
0
+772.7%
0
-37.1%
0
-46.2%
0
-35.6%
0
Goodwill
—
—
—
—
8
-7.8%
9
+9.5%
8
-1.9%
8
-4.7%
9
Total assets
21
-38.9%
35
+47.7%
24
-14.7%
28
-65.2%
80
+116.5%
37
+85.2%
20
-20.1%
25
+12.7%
22
Liabilities and equity
Total current liabilities
4
-50.0%
7
+450.9%
1
-81.4%
7
-9.3%
8
+63.8%
5
-16.2%
6
+1.1%
6
-3.0%
6
Total liabilities
18
-19.7%
22
+708.5%
3
-32.6%
4
-85.2%
27
+14.0%
24
+6.0%
22
-2.9%
23
-7.5%
25
Debt
Lease liabilities
2
-7.0%
2
+36.0%
2
-12.1%
2
+1100.0%
0
-12.5%
0
-79.6%
1
—
—
Total debt
2
-7.0%
2
+36.0%
2
-12.1%
2
+1100.0%
0
-12.5%
0
-79.6%
1
—
—
Net cash
5
-63.4%
14
+182.8%
5
-39.7%
8
+37.7%
6
-75.1%
24
+247.3%
7
—
—
Ratios
Current ratio
3.18x
3.32x
8.59x
7.88x
9.12x
5.82x
1.93x
2.90x
1.63x
Debt to EBITDA
—
—
—
0.33x
—
—
—
—
—
Return on assets
-48.33%
-43.65%
-14.68%
12.39%
-10.45%
-13.83%
-30.24%
16.74%
-75.67%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Perfumes, Cosmetics & Other Toilet Preparations (SIC 2844)
Listed as
CSCIF (OTC)
Fiscal year ends
December 31
Incorporated in
Ontario, Canada
Headquarters
Toronto, Ontario, Canada
SEC filer status
Non-accelerated filer
SEC CIK
1113423
Former names
Aeterna Zentaris Inc. (until Aug 7, 2024); AETERNA LABORATORIES INC (until May 25, 2004)

Other Perfumes, Cosmetics & Other Toilet Preparations companies

All 22 Perfumes, Cosmetics & Other Toilet Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.